Description

Viking 1 (GHRP-2 + GHRP-6 + Sermorelin) Peptide Vials

Viking 1 consists of 20mg GHRP-2, 6mg GHRP-6, and 15mg Sermorelin, totaling 41mg.

GHRP-2
CAS Number	158861-67-7
Molar Mass	817.992 g·mol−1
Chemical Formula	C45H55N9O6
IUPAC Name	(2S)-6-Amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide

GHRP-6
CAS Number	87616-84-0
Molar Mass	873.032 g·mol−1
Chemical Formula	C46H56N12O6
IUPAC Name	L-histidyl-D-tryptophyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-Lysinamide

Sermorelin
CAS Number	86168-78-7
Molar Mass	3357.93 g·mol−1
Chemical Formula	C149H246N44O42S
IUPAC Name	L-Tyrosyl-L-alanyl-L-α-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-argininamide

Introduction

Welcome to the world of Viking, a unique research peptide combining GHRP-2, GHRP-6, and Sermorelin. This innovative blend is designed exclusively for laboratory and research purposes.

Key Characteristics

Viking is a fusion of three peptides known for their potential impact on growth hormone (GH) release. GHRP-2 and GHRP-6 stimulate the secretion of GH, while Sermorelin acts as a growth hormone-releasing hormone (GHRH) analog, collectively aiming to enhance research in the field of endocrinology.

Research Applications

The Viking peptide, when utilized in a controlled laboratory environment, serves as a valuable tool for studying the intricate mechanisms involved in GH release regulation. Researchers can explore its effects on cellular growth, metabolism, and various physiological processes.

Research Benefits

Potential Synergistic Effects

Viking’s unique combination of GHRP-2, GHRP-6, and Sermorelin opens avenues for investigating potential synergistic effects on GH release. Studies suggest that the interplay between these peptides may lead to enhanced outcomes compared to individual peptides.

GHRP-2 May Improve Muscle Growth

Exploratory research indicates that GHRP-2, one of Viking’s components, may contribute to improved muscle growth. This aspect invites further investigation into the peptide’s mechanisms and potential applications in muscle-related studies.

GHRP-6 and Obesity

Preliminary studies propose that GHRP-6, another constituent of Viking, may play a role in addressing obesity-related concerns. Research in this area can shed light on the peptide’s impact on metabolism and body composition.

Sermorelin and GH

Sermorelin’s function as a GHRH analog prompts intriguing research possibilities regarding its influence on growth hormone release. Investigations into its interaction with GH pathways can contribute to a deeper understanding of endocrine dynamics.

Summary

In conclusion, Viking (GHRP-2 + GHRP-6 + Sermorelin) Peptide is a promising research tool with the potential for synergistic effects on GH release. Its components, GHRP-2, GHRP-6, and Sermorelin, offer specific avenues for exploration in muscle growth, obesity-related studies, and understanding the dynamics of growth hormone release. Researchers are encouraged to delve into these areas to expand our knowledge of endocrinology.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon finalizing your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. If you are dissatisfied with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Maletínská L, Matyšková R, Maixnerová J, Sýkora D, Pýchová M, Spolcová A, Blechová M, Drápalová J, Lacinová Z, Haluzík M, Zelezná B. The Peptidic GHS-R antagonist [D-Lys(3)]GHRP-6 markedly improves adiposity and related metabolic abnormalities in a mouse model of postmenopausal obesity. Mol Cell Endocrinol. 2011 Aug 22;343(1-2):55-62. doi: 10.1016/j.mce.2011.06.006. Epub 2011 Jun 17. Erratum in: Mol Cell Endocrinol. 2012 Jan 2;348(1):344. PMID: 21704671. [Read More].
2. Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992 Aug;75(2):530-5. doi: 10.1210/jcem.75.2.1379256. PMID: 1379256. [Read More].
3. Yamamoto D, Ikeshita N, Matsubara T, Tasaki H, Herningtyas EH, Toda K, Iida K, Takahashi Y, Kaji H, Chihara K, Okimura Y. GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1. Life Sci. 2008 Feb 27;82(9-10):460-6. doi: 10.1016/j.lfs.2007.11.019. Epub 2007 Dec 5. PMID: 18191156. [Read More].